News | December 05, 2022
Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
One in two women with advanced ovarian cancer has an HRD-positive tumor
Subscribe To Our Newsletter & Stay Updated
